Fig. 1: ALKBH5 is related to the occurrence of pathological cardiac hypertrophy.

A, B The transcriptional profile of ALKBH5 was analyzed in the published human RNA-sequencing (RNA-seq) data (GSE116250) comprising with normal myocardium (Control, n = 12), patients with dilated cardiomyopathy (DCM, n = 35), and patients with ischemic cardiomyopathy (ICM, n = 11) and the published human RNA-seq data (GSE179107) including 229 human DCM samples and 34 controls. Gene expression analysis was conducted using the t-test method after filtering. P = 0.00024965 in ICM and P = 0.019031 in DCM, compared to the normal myocardium (Control) in GSE116250. P < 2.2 × 10⁻¹⁶ in DCM, compared to the normal myocardium (Control) in GSE179107. C ALKBH5 and ANP protein levels were detected by immunoblotting in the hearts of mice subjected to sham or TAC surgery (n = 3). D The qRT-PCR assay was performed to detect the mRNA level of Alkbh5 gene in TAC-induced cardiac hypertrophy (n = 3). E Representative images and quantitation of immunohistochemical staining of ALKBH5 in the hearts of mice subjected to sham or TAC surgery. F, G Mice were fed a high fat diet (HFD) or normal diet (ND) for 12 weeks and the hearts were harvested. Western blots and qRT-PCR assays were performed to detect the protein and mRNA levels of ALKBH5, as well as hypertrophic biomarkers ANP and MYH6 protein or mRNA levels. n = 3 per group, data shown are means ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.